Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Sector:
Health Services
Industry:
Medical Or Nursing Services
Employees:
N/A
Frequently Asked Questions
What is Market Cap of GRAIL Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. GRAIL Inc. market cap is $480.95M.
What is the 52-week high for GRAIL Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. GRAIL Inc. 52 week high is $19.00 as of July 04, 2024.
What is the 52-week low for GRAIL Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. GRAIL Inc. 52 week low is $14.20 as of July 04, 2024.
What is GRAIL Inc. stock price today?
GRAIL Inc. stock price today is $15.49.
What was GRAIL Inc. stock price yesterday?
GRAIL Inc. stock price yesterday was $15.05.
What is the Price-to-Book ratio of GRAIL Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. GRAIL Inc. P/B ratio is 0.1286.
What is the 50-day moving average of GRAIL Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. GRAIL Inc. 50-day moving average is $15.68.